Descripción de la empresa
Abpro Corporation, operating under the ticker ABP, is a biotechnology enterprise dedicated to developing novel antibody constructs specifically targeted toward immuno-oncology and ophthalmology applications. The company's strategic platforms include DiversImmune, a discovery mechanism designed to generate a diverse collection of proprietary antibodies against both clinically validated and novel targets, alongside its MultiM platform. This entity operates within the broader Healthcare sector, specifically classified under the Biotechnology industry, positioning it as a specialized player in the pursuit of advanced therapeutic solutions. The organization maintains a very small operational scale, employing only six individuals while holding a total market capitalization of $1.42 million. When analyzing the financial magnitude, the market cap figure combined with the absence of reported annual revenue indicates that the company functions as a micro-cap entity focused on early-stage research and development rather than commercialized product sales. The minimal employee count of six further underscores that the firm is likely in an exploratory phase where human resources are concentrated on scientific discovery rather than large-scale manufacturing or distribution operations.
Salud financiera
The company reports a Net Income (TTM) of $-22,040,000 and an EBITDA of $-9,301,000, while the Revenue (TTM) is listed as N/A. The significant negative net income relative to the reported EBITDA, in the absence of substantial revenue, reveals a cost structure where operational expenses and research expenditures vastly exceed any current commercial income generation. Despite these operating losses, the Free Cash Flow stands at $6.37M, which suggests a degree of financial flexibility potentially derived from asset sales or other non-operating cash inflows, allowing the firm to fund its R&D without immediate reliance on external financing. The company holds $328,000 in cash assets against a total debt load of $147,000, creating a net cash position that appears conservative on a raw balance sheet basis. However, the Price to Book ratio of -0.09 and the Return on Assets of -229.6% indicate a balance sheet that is currently distressed or highly leveraged in terms of equity erosion rather than traditional debt burden. The Current Ratio is recorded at 0.07, a figure that critically indicates severe short-term liquidity constraints, as current liabilities significantly outweigh current assets. Furthermore, the Return on Equity is N/A due to the negative equity position, while the Return on Assets of -229.6% reveals that management has been ineffective at generating value from the company's asset base in the trailing twelve-month period.
Evaluación de valoración
The Trailing Twelve Months P/E Ratio and Forward P/E are both listed as N/A, reflecting the company's status as a non-profitable entity where traditional earnings-based valuation metrics are inapplicable. The Price to Book ratio is -0.09, indicating that the market is valuing the company at a fraction of its book value, a common characteristic for pre-revenue biotech firms with negative equity. The Price to Sales ratio is infinite (inf), as there is no reported revenue to serve as a denominator, while the EV/EBITDA stands at -0.19, suggesting a negative enterprise value relative to earnings power. In terms of trading range, the 52-Week High is $18.03 and the 52-Week Low is $0.11, meaning the current valuation sits within an extremely wide volatility band with no specific percentage distance calculable without a real-time price. The Beta is recorded as -0.00, a unique statistical anomaly that implies the stock's price movement has no linear correlation with the broader market index, effectively isolating its volatility profile from standard market trends. These metrics collectively suggest a high-risk valuation profile where investors are pricing in potential future clinical milestones rather than current financial performance.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a quantitative comparison of whether earnings are growing faster or slower than revenue at this stage of development. Since the company does not pay dividends, the Dividend Yield and Payout Ratio are N/A and 0.0% respectively, confirming that the firm reinvests all available resources and earnings back into its research and development initiatives rather than distributing income to shareholders. The absence of a payout ratio implies that the company prioritizes capital expenditure for its antibody constructs and platform development over shareholder returns. Consequently, the overall growth and income profile is defined entirely by its potential for future commercialization of its immuno-oncology and ophthalmology assets, as there is no current stream of dividend income or historical revenue growth data to evaluate past expansion. The firm's financial trajectory relies exclusively on the successful execution of its novel antibody constructs to transition from negative earnings to positive revenue generation in the future.